Advanced Wearable Insulin Pump System with Real-time Medication Occlusion Detection and Personalized Dosage Recommendations

Publication ID: 24-11857757_0001_PTD
Published: November 07, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Advanced Wearable Insulin Pump System with Real-time Medication Occlusion Detection and Personalized Dosage Recommendations,” Published Technical Disclosure No. 24-11857757_0001_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857757_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,757.

Summary of the Inventive Concept

An enhanced wearable insulin pump system that integrates real-time medication occlusion detection, automatic dosage adjustment, and personalized dosage recommendations to improve the safety and efficacy of medication delivery for diabetes patients.

Background and Problem Solved

The original patent, 'Systems and methods for delivering microdoses of medication,' has limitations in detecting medication occlusion and adjusting dosages accordingly. This new inventive concept addresses these limitations by incorporating advanced sensors and data analytics capabilities to ensure accurate and personalized medication delivery.

Detailed Description of the Inventive Concept

The advanced wearable insulin pump system comprises a patch pump with a built-in sensor for detecting medication occlusion. Upon detection, the system automatically adjusts the dosage accordingly. Additionally, the system includes a data analytics module that tracks the user's medication adherence and provides personalized dosage recommendations based on the user's glucose levels, activity data, and other relevant factors. The system also includes a mobile application for tracking the user's medication schedule and sending reminders and alerts.

Novelty and Inventive Step

The new inventive concept's novelty lies in the integration of real-time medication occlusion detection and automatic dosage adjustment, which is not present in the original patent. The inventive step is the use of advanced sensors and data analytics capabilities to personalize medication delivery and improve patient safety.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of sensors, such as optical or acoustic sensors, to detect medication occlusion. Additionally, the system could be integrated with other health monitoring devices, such as continuous glucose monitors, to provide a more comprehensive picture of the user's health.

Potential Commercial Applications and Market

The advanced wearable insulin pump system has significant commercial potential in the diabetes management market, which is expected to grow significantly in the coming years. The system's ability to improve patient safety and efficacy makes it an attractive solution for patients, healthcare providers, and payers.

CPC Classifications

SectionClassGroup
A A61 A61M5/14248
A A61 A61B5/14865
A A61 A61M5/1413
A A61 A61M5/158
A A61 A61M5/168
A A61 A61M5/1684
A A61 A61M5/16827
A A61 A61M5/172
A A61 A61M5/1723
A A61 A61M5/5086
A A61 A61M2005/14252
A A61 A61M2005/14256
A A61 A61M2005/14533
A A61 A61M2005/1586
A A61 A61M2205/18
A A61 A61M2205/3317
A A61 A61M2205/3331
A A61 A61M2205/582
A A61 A61M2207/00

Original Patent Information

Patent NumberUS 11,857,757
TitleSystems and methods for delivering microdoses of medication
Assignee(s)Tandem Diabetes Care Switzerland Sàrl